Reimagining Drug Delivery for Solid Tumors
Infinova Biosciences is developing a first-in-class, cell-based drug delivery platform to overcome the physical barriers of hard-to-treat solid tumors.
Company
Infinova Biosciences is led by experienced biotech veterans with decades of experience in drug development and asset management.
Science
Our groundbreaking CAR-neutrophil drug delivery platform combines cellular engineering and nanotechnology to overcome the challenges of getting drugs to brain tumors.
News & Media
Join us in transforming cancer treatment by supporting a cutting-edge therapeutic platform with the potential to finally overcome an historical medical challenge.
Become An Investor
Infinova Biosciences offers a compelling value proposition for investors seeking to support transformative innovation in oncology.
Glioblastoma remains one of the most aggressive and treatment-resistant cancers, with current therapies failing to address critical challenges, mainly drug delivery across the blood-brain barrier (BBB) and deep tumor penetration. Infinova’s state-of-the-art CAR-neutrophil drug delivery platform directly addresses both of these unmet needs, combining next-gen cellular engineering with nanoparticle technology to deliver therapeutics precisely where they are needed.
Backed by robust preclinical data, our platform has the potential to revolutionize glioblastoma treatment and capture significant market share in CNS oncology. By investing in Infinova, you are not only supporting cutting-edge science but also positioning yourself at the forefront of a high-impact therapeutic solution with strong clinical and commercial potential.